Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesAssociation between colorectal cancer and urologic cancers
Archives of Internal Medicine, 05/13/08
Calderwood AH et al. – Previous findings on renal pelvis/ureteral cancer and a follow up of the history of colorectal cancer (CRC) supports a possible common pathogenetic mechanism between CRC and urologic cancers and may have implications for screening guidelines.
Methods- Study to quantify the risk for CRC after urologic cancer and the risk for urologic cancer after CRC in pts w/o known genetic syndromes
- A retrospective cohort analysis of the Surveillance, Epidemiology, and End Results from program database from 1973 to 2000 was performed
- Standard incidence ratios (SIRs) of observed to expected cases of invasive CRC were calculated for each urologic cancer site based on age, sex, ethnicity, and calendar year of diagnosis
- Similar analysis was performed to determine the SIRs of urologic cancers in pts with previous CRC
- Overall, the risk for CRC was increased among pts with previous ureteral cancer and renal pelvis cancer
- This risk was greatest among pts who received the diagnosis of renal pelvis or ureteral cancer before the age of 60 yrs
- There was a minimal increased risk for subsequent CRC in pts with bladder or renal parenchymal cancer
- Overall, the risk for urologic cancer was increased after a diagnosis of CRC
- Highest risk for subsequent renal pelvis and ureteral cancers was observed in pts with a CRC diagnosis before the ages of 50-60 yrs or multiple primary CRCs
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09
Article Search
Sponsor